What is the target LDL level for high-intensity statin therapy in atherosclerotic cardiovascular disease?

In the context of high-intensity statin therapy for individuals with atherosclerotic cardiovascular disease (ASCVD), the target LDL (low-density lipoprotein) cholesterol level is typically set at less than 1.8 mmol/L. This target is based on evidence suggesting that lowering LDL levels below this threshold significantly reduces the risk of cardiovascular events in patients with established ASCVD.

High-intensity statin therapy is indicated for patients with a history of heart attacks, strokes, or other forms of cardiovascular disease because it effectively lowers LDL cholesterol and has been shown to provide substantial cardiovascular protection. The goal of achieving an LDL level under 1.8 mmol/L is designed to optimize clinical outcomes by reducing the overall risk of further cardiovascular issues.

Knowing this target is crucial for healthcare professionals when managing cholesterol levels in patients with atherosclerotic cardiovascular disease, thus guiding treatment decisions and monitoring effectiveness over time.